People · Operator
Named in public records as an officer, director or promoter · active 2021–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Orchard Therapeutics plc | — | Biotechnology | Series D+ | $184.0M | $576.3M | 2021 |
Bobby Gaspar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bobby Gaspar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven M. Altschuler | 1 | 3 |
| Frank E. Thomas | 1 | 3 |
| James A. Geraghty | 1 | 3 |
| Joanne T. Beck | 1 | 2 |
| John T. Curnutte | 1 | 1 |
| Steven E. Altschuler | 1 | 1 |
| Jon T. Ellis | 1 | 1 |
| Marc T. Dunoyer | 1 | 1 |
| Alicia A. Secor | 1 | 1 |
| Charles A. Rowland, Jr. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.